Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
With the deeper understanding of the pathophysiology and pathogenesis of non-small cell lung cancer (NSCLC) which threatens human health, NSCLC treatment has entered a new era. Transition from traditional treatment based on surgery, radiotherapy and chemotherapy to individualized and precise targeted therapy and safer and more effective immunotherapy. Immune checkpoint inhibitor therapy has been approved as a first-line or second-line treatment for advanced NSCLC, and has achieved extraordinary clinical results. Meanwhile, other types of immunotherapy are rarely explored in NSCLC. Chimeric antigen receptor modified T cells (CAR-T cells) perform well in treating several hematological malignancies. However, it is not ideal for treating patients with solid tumors including NSCLC. This review aims to systematically explain the latest progress of CAR-T in the treatment of NSCLC, mainly including: CAR molecular target selection, CAR-T function enhancement and related toxicity management, as well as the difficulties and prospects of CAR-T treatment of NSCLC. It aims to open up new perspectives and unique ideas for the immunotherapy of NSCLC, and contribute to the building of tumor immunotherapy. .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583876 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiogenomics-based prediction of and gene mutation in non-small cell lung cancer patients.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Geriatric Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008.
Objectives: Non-small cell lung cancer (NSCLC) is associated with poor prognosis, with 30% of patients diagnosed at an advanced stage. Mutations in the and genes are important prognostic factors for NSCLC, and targeted therapies can significantly improve survival in these patients. Although tissue biopsy remains the gold standard for detecting gene mutations, it has limitations, including invasiveness, sampling errors due to tumor heterogeneity, and poor reproducibility.
View Article and Find Full Text PDFTargeting the Toll-like Receptor Signaling Pathway in Lung Cancer: Therapeutic Opportunities and Challenges.
Curr Drug Targets
September 2025
Center for Developmental Biology, School of Life Science, Anhui Agricultural University, 230036, Hefei, China.
Lung cancer, particularly non-small cell lung cancer, is a leading cause of global mortality, with many cases diagnosed at advanced stages. The Toll-Like Receptor (TLR) signaling pathway plays a crucial role in linking inflammation to lung cancer progression, with both pro-tumor and anti-tumor effects. This perspective delves into the complex functions of TLR proteins in lung cancers, elucidating their involvement in tumor growth, angiogenesis, and metastasis.
View Article and Find Full Text PDFDriver Genes and Genomic Instability Predict the Incidence and Outcome of Brain Metastases.
Curr Cancer Drug Targets
September 2025
Department of Critical Care Medicine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, 358 Datong Road, Pudong New District, Shanghai 200137, China.
Introduction: The incidence of brain metastases in patients diagnosed with ad-vanced lung cancer is high, drawing significant attention to the risk factors associated with this progression.
Methods: A total of 252 advanced non-small cell lung cancer (NSCLC) patients with brain metastases were enrolled in this study between July 2018 and December 2023 from our hos-pital. Additionally, driver genes, including EGFR, ALK, ROS1, KRAS, and RET, were doc-umented.
Unilateral cystic and bullous lung changes in a patient treated with brigatinib: a case report.
Korean J Clin Oncol
August 2025
Department of Clinical Medicine (IKM), University of Copenhagen, Copenhagen, Denmark.
Approximately 3% to 5% of individuals with oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene develop non-small cell lung cancer (NSCLC). Brigatinib, a potent next-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated significant systemic and intracranial responses, as well as improved progression-free survival, with an acceptable safety profile. According to European Society for Medical Oncology guidelines patients with ALK translocation and performance status 0-3 can be offered 1st line treatment with TKI (brigatinib, alectinib, or lorlatinib).
View Article and Find Full Text PDFEstablishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent.
Bioorg Chem
August 2025
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:
HDAC inhibitors, which have been proven to be effective for some cancers, have potential as treatments for Non-small cell lung cancer (NSCLC). Building on the core structure of the highly selective HDAC6 inhibitor J22352, we modified various zinc-binding groups of this inhibitor. The resulting compounds 1-8 were designed and synthesized to explore potential derivatives and assess their effects on NSCLC bioactivity.
View Article and Find Full Text PDF